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ABSTRACT
Introduction Motor neuron disease (MND) is a rapidly 
progressive and fatal neurodegenerative disorder with 
limited treatment options. The Motor Neuron Disease 
Systematic Multi- Arm Randomised Adaptive Trial (MND- 
SMART) is a multisite UK trial seeking to address the 
paucity in effective disease- modifying drugs for people 
with MND (pwMND). Historically, neurological trials have 
been plagued by suboptimal recruitment and high rates 
of attrition. Failure to recruit and/or retain participants can 
cause insufficiently representative samples, terminated 
trials or invalid conclusions. This study investigates 
patient- specific factors affecting recruitment and retention 
of pwMND to MND- SMART. Improved understanding of 
these factors may improve trial protocol design, optimise 
recruitment and retention.
Methods and analysis PwMND on the Scottish MND 
Register, Clinical Audit Research and Evaluation of MND 
(CARE- MND), will be invited to participate in a prospective 
observational cohort study that investigates factors 
affecting trial participation and attrition. We hypothesise 
that patient- specific factors will significantly affect trial 
recruitment and retention. Participants will complete the 
Hospital Anxiety and Depression Scale, 9- Item Patient 
Health Questionnaire and State- Trait Anxiety Inventory- 
Form Y to evaluate neuropsychiatric symptoms, the 
ALS- Specific Quality of Life Questionnaire- Brief Form 
and Centre for Disease Control and Prevention- Health- 
Related Quality of Life for quality of life and a novel 
study- specific questionnaire on Attitudes towards Clinical 
Trial Participation (ACT- Q). Clinical data on phenotype, 
cognition (Edinburgh Cognitive and Behavioural ALS 
Screen) and physical functioning (Amyotrophic Lateral 
Sclerosis Functional Rating Scale- Revised) will also be 
collated. Caregivers will complete the Brief Dimensional 
Apathy Scale. After 12 months, a data request to MND- 
SMART will evaluate recruitment and retention. Descriptive 
statistics will summarise and compare assessments and 
participants reaching impairment thresholds. Variable 
groupings: attitudes, quality of life, cognition, behaviour, 
physical functioning, neuropsychiatric and phenotype. 
Univariate and multivariable logistic regression will explore 
association with participation/withdrawal in MND- SMART; 
presented as ORs and 95% CIs.
Ethics and dissemination Ethical approval was provided 
by the West of Scotland Research Ethics Committee 3 
(20/WS/0067) on 12 May 2020. The results of this study 
will be published in a peer- reviewed journal, presented at 
academic conferences and disseminated to participants 
and the public.
INTRODUCTION
Clinical trials in motor neuron disease
Motor neuron disease (MND) is a rapidly 
progressive, incurable and uniformly fatal 
neurodegenerative disorder. Mean age of 
onset is 65.3 years and only 51.3% of people 
with MND (pwMND) survive more than 12 
months from diagnosis.1 The disorder has 
a significant impact on multiple aspects of 
an individual’s life necessitating a holistic 
approach to clinical care and trial design.
There is an urgent need for new therapies 
in MND. Only one disease- modifying therapy, 
riluzole, has been approved for treatment 
in the UK, with limited impact on median 
survival.2 The recently published Airlie House 
guidelines encapsulate the new direction of 
trials in this area; with clear recommenda-
tions to rethink outcome measures, stratify 
participant characteristics and use academic 
Strengths and limitations of this study
 ► The first observational cohort study prospective-
ly assessing factors influencing people with motor 
neuron disease to participate, and remain in, a clin-
ical trial.
 ► Better understanding of factors that affect recruit-
ment and retention can inform future trial design.
 ► Impossible to account for all potential influences on 
the variability in human behaviour.
 ► As the population is Scotland- based, there may be 
additional barriers to participation or factors affect-
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consensus and historical trial findings to inform future 
design.3
Recruitment and retention in MND trials
The accurate identification of factors that impact on 
recruitment and retention of participants in research 
studies is important when considering trial design.4 
Recruitment should involve selection of participants 
representative of the target population, in numbers suffi-
cient to fulfil trial- specific power calculations. Previously, 
while restrictive inclusion criteria have been advantageous 
to stratify a heterogeneous population to detect an effect, 
results from these studies may not be readily generalis-
able, and restrict opportunities for research participation. 
While 83% of pwMND indicated that they would be open 
to participating in research trials,5 surveyed clinicians esti-
mate enrolment figures of 25% in trials, primarily due to 
unsuitability of pwMND within stated inclusion criteria.6
Trials have utilised narrow inclusion criteria in an 
attempt to stratify subgroups, however, this may impact 
on homogenisation of trial outcomes at the cost of inclu-
sivity.7 As MND- SMART (Motor Neuron Disease System-
atic Multi- Arm Adaptive Trial) involves broader inclusion 
criteria than many previous trials, we expect higher rates 
of enrolment.
Attrition is defined as the loss of participating indi-
viduals to follow- up or as a result of missing data at one 
of more time- points.8 While some attrition is inevitable, 
ensuring optimal retention is an important consideration 
in trial design. Clinical trials in pwMND frequently report 
attrition rates over 20%;9 10 risk of bias is high at attrition 
rates in this threshold.11 Any level of attrition may result 
in bias in results reported as the characteristics of those 
individuals remaining, versus those lost to follow- up or 
with significant levels of missing data, may differ.
Suboptimal recruitment and retention can affect a 
study’s power, in turn significantly impacting conclu-
sions.12 These methodological issues can lead to trials 
reporting invalid or inconclusive results, prolonged trial 
times and potential premature termination.4 13 Further 
investigation of factors that may account for variability 
in recruitment and retention, particularly within MND, 
is essential to devise strategies to address issues in enrol-
ment and attrition and improve trial delivery.
New directions in MND trials
MND- SMART is a multisite UK clinical trial, which seeks to 
evaluate the effects of repurposed medicines with poten-
tial neuroprotective properties. Full details of the trial 
design and selection criteria are available at  clinicaltrials. 
gov (NCT04302870) and EudraCT (Trial record number: 
2019-000099-41). MND- SMART is a long- running trial, 
expected to evaluate several candidate repurposed 
drugs over the next two decades under a single umbrella 
protocol. Currently, memantine and trazodone are being 
evaluated against placebo.
Primary objectives are to assess the impact of these 
candidate drugs on functional ability, as measured using 
the Amyotrophic Lateral Sclerosis Functional Rating 
Scale- Revised (ALS- FRS(R)),14 and also on survival. 
Secondary outcomes include the impact of these medi-
cines on cognition, respiratory functioning, affective 
symptoms and quality of life in pwMND.
The multiarm, multistage, adaptive design has been 
shown to be particularly beneficial in enabling a reduc-
tion of patient numbers and time required to test more 
than one candidate drug in later stage trials of stroke15 
and cancer16. These may be particularly crucial changes 
in trial delivery for rarer and higher- burden diseases 
such as MND. Broad inclusion criteria intend to promote 
participation and ensure that the trial is available to a 
large number of pwMND, ultimately intending to capture 
the heterogeneity of this condition and improve the 
generalisability of findings. Establishing multiple stages 
with predefined interim analysis also reduces the chance 
of a patient taking an ineffective drug for longer than 
necessary, crucial in a condition with such a short life 
expectancy.
Rationale
A review of clinical trials in oncology17 identified three 
areas that impact on recruitment: patient factors, trial 
factors and doctor factors. This concept was also reflected 
in Atassi’s5 review of factors affecting adherence in MND 
trials; study population characteristics, trial design and 
site/staff facilities. MND- SMART seeks to address many 
trial factors such as inclusive trial participant criteria, 
remote follow- up appointments to address progressive 
disability and liquid medication to minimise potential 
swallowing difficulties.
In MND- SMART, many of the trial and doctor- specific 
factors that have previously affected engagement with 
MND trials have been addressed. This provides us with 
a unique opportunity to explore how patient- specific 
factors can also influence trial participation decisions. 
Although focused on a single trial, we believe these find-
ings will inform future trial design, promote inclusivity 
and support trial teams in retaining participants.
The presence of neuropsychiatric conditions, behaviour 
change and cognitive impairment pose significant chal-
lenges for recruitment and can impact on a person’s 
ability to give informed consent and adhere to study 
protocol.5 18 Participants’ demographic characteristics19 20 
and attitudes towards research and health behaviours21 
may also be predictive of trial enrolment and attrition.
However, we currently have no knowledge of how prev-
alent and impactful these patient- specific factors are on 
pwMND and their decision to participate and remain in 
a clinical trial. This study will seek to address this knowl-
edge gap, exploring what factors define the trial ‘partici-
pant’ and are associated with retention at follow- up.
Aims and hypothesis
This prospective observational cohort study will investi-
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and retention within the context of the first multi- arm 
multicentre UK clinical trial in MND.
Aims
1. Evaluate the characteristics of individuals who do, or 
do not, participate in MND- SMART
2. Compare the characteristics of FIT- P- MND participants 
who remain enrolled on MND- SMART after 12 months 
and those who are lost to follow- up
Hypothesis
We hypothesise that patient- specific factors, such as neuro-
psychiatric symptoms, cognitive impairment, behavioural 
change, phenotype, quality of life and physical func-
tioning will significantly impact on pwMND’s decision to 
participate, and remain in, MND- SMART.
METHODS
Study design
This prospective observational cohort study will evaluate 
how patient- specific factors in pwMND affect their partici-
pation in MND- SMART, a multi- arm UK- wide clinical trial.
Using a range of assessments this study will evaluate 
patient- specific factors in pwMND at a specific point in 
time: neuropsychiatric symptoms (specifically depression, 
anxiety and suicidality), apathy, attitudes to clinical trials 
and quality of life. This will be supplemented with clin-
ical care data and trial participation data derived from 
the individual’s Clinical Audit Research and Evaluation 
of MND (CARE- MND) register record, and MND- SMART 
data if they choose to also participate in the trial.
After 12 months, we will use an additional data 
request to MND- SMART to explore which of the FIT- 
P- MND participants also joined the trial, and of these, 
who remains enrolled in the trial after 12 months. This 
study will explore how the patient- specific factors, evalu-
ated through questionnaires and clinical data, impacted 
on the recruitment to, and retention of, this cohort of 
pwMND to MND- SMART.
CARE-MND register
The FIT- P- MND project will use CARE- MND to facilitate 
recruitment, access clinicaldata for pwMND living in 
Scotland.
Established in 1989, the Scottish Motor Neuron Disease 
Register was the first population- based register for MND 
in the world.22 In 2015, the register was relaunched as 
the electronic platform CARE- MND. This has facilitated 
detailed longitudinal phenotyping of pwMND in Scot-
land from diagnosis to death, with allied tissue and brain 
banks and a research interest register allowing pwMND 
the ability to register interest in future observational and 
interventional studies.23 The CARE- MND register has 
99% case ascertainment for pwMND in Scotland where 
there is an incidence of 180–220 new cases a year, and a 
prevalence of approximately 450 pwMND.23 FIT- P- MND 
will focus on Scottish participants.
Stages of study
This study will involve three time- points of data collection, 
with participants directly involved in the first stage only:
1. Questionnaire completion: participant and caregiver 
questionnaire packs.
2. CARE- MND data request: additional covariates collect-
ed in routine clinical care.
3. MND- SMART data request: trial involvement and 
participation.
Study Timeline
Timeline for the current study was impacted by the 
COVID-19 pandemic, as non- COVID research and 
recruitment was temporarily halted. Table 1 provides an 
overview for key time points in the study, and projected 
dates for recruitment and data collection.
Recruitment
All individuals on the CARE- MND register who have 
consented to receive information on studies which they 
may be eligible for will be invited to participate in FIT- 
P- MND via a postal invitation pack.
Potential FIT- P- MND participants will receive this 
postal pack with information on the study and a Consent 
Form. They will also be asked to identify a caregiver who 
would be willing to complete a behaviour questionnaire 
and they will receive a separate Consent Form and Infor-
mation Sheet.
Participants can indicate on their Consent Form their 
preferred completion method; online survey, in- person 
appointment in Edinburgh, postal or telephone. These 
options have been selected to maximise accessibility and 
inclusivity.
Sample size considerations
This study will aim to recruit a sample of 120 individuals 
with a diagnosis of MND.
The required sample size was determined using the 
primary research objectives, which will be answered using 
regression analysis. The calculation is based on the use of 
a logistical regression model, as recruitment of pwMND 
Table 1 Overview of FIT- participation- MND study timeline
Key study aspect Actual or projected date
Favourable ethical opinion 
obtained
12 May 2020
Site approval to commence 
recruitment
8 July 2020
Recruitment commences 10 August 2020
Recruitment planned to close March 2021
CARE- MND data request March 2021
MND- SMART data request March 2022
CARE, Clinical Audit Research and Evaluation ; FIT, factors 
influencing trial; MND, motor neuron disease ; SMART, Systematic 
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to the MND- SMART clinical trial is a binary outcome vari-
able (yes/no to participation).
An OR (measure of association between an exposure 
and an outcome) of 1.70 with power at 0.70 provides a 
sample size estimate of 111.
There are around 420 pwMND in Scotland at any point 
in time, circa 220 of whom have provided consent on 
CARE- MND to be contacted about research. All partici-
pants on the CARE- MND register who are eligible will be 
invited to participate.
Previous research using postal questionnaires in 
pwMND reports a responserate of 63%.24 However, we 
anticipate that adding the options of completion via 
online survey or telephone will improve response rates. 
As a result, we expect 120 individuals to be an obtainable 
sample size, based on a 60% response rate estimate.
Across all Scottish sites, the MND- SMART projected 
recruitment is 100 participants per year, with attrition 
due to death or withdrawal predicted at 20% annually. 
We estimate that around 80% of the 120 participants in 
FIT- P- MND will also enrol in MND- SMART, 100 people. 
Based on projected annual attrition rates of 20% for 
MND- SMART, we expect 80 of these individuals to remain 
in MND- SMART 12 months later.
As this is an exploratory study, looking at nine variables 
(using grouping to simplify analysis and presentation), 
and a relatively rare condition, sample size is based on the 
number of potential participants available and descriptive 
analysis methods will be utilised to explore the data.
Study assessments
Table 2 includes a summary of all study assessments 
included in FIT- P- MND participant and caregiver 
engagement and data requests. The questionnaire set 
for pwMND will take around 45 minutes, depending on 
physical decline and speech impairment, and includes 
; Hospital Anxiety and Depression Scale, 9- Item Patient 
Health Questionnaire and State- Trait Anxiety Inventory- 
Form Y. FIT- P- MND participants will also be invited to 
questionnaires on quality of life: ALS- Specific Quality of 
Life Questionnaire- Brief Form and Centre for Disease 
Control and Prevention- Health- Related Quality of Life. 
Finally, participants will be asked to complete the Atti-
tudes towards Clinical Trial Participation Questionnaire 
to evaluate attitudes towards trial participation. Care-
givers will be invited to complete the Brief Dimensional 
Apathy Scale to consider behavioural changes of the 
participant (circa 5 minutes). Questionnaires will take 
around 50 minutes in total.
Data requests to CARE- MND and MND- SMART for 
additional data on physical functioning, cognition and 
clinical phenotype enable us to reduce burden on partic-
ipants by ensuring brevity in study visits. We will use ALS- 
FRS(R) and Edinburgh Cognitive and Behavioural ALS 
Screen scores from CARE- MND, or MND- SMART if the 
individual is also a trial participant, to ensure we collect 
scores closest to the time- point that the FIT- P- MND study 
assessments are undertaken.
Inclusion/exclusion criteria
Table 3 summarises the inclusion and exclusion criteria 
for pwMND and their caregivers who wish to partici-
pate in FIT- P- MND. These criteria have been primarily 
Table 2 Study assessments, CARE- MND and MND- 
SMART data requests
Data source Name of assessment
Study assessment 
questionnaires: FIT- P- 
MND participant with 
MND
ACT- Q (Attitudes towards Clinical 
Trial Participation Questionnaire)
HADS (Hospital Anxiety and 
Depression Scale)27 28
STAI- Y (State- Trait Anxiety 
Inventory- Form Y)29
PHQ-9 (9- Item Patient Health 
Questionnaire)30 31
ALSSQOL-20 (ALS- Specific 
Quality of Life Questionnaire- Brief 
Form)32
CDC HQOL-4 (Centre for Disease 
Control and Prevention- Health- 




b- DAS (Brief Dimensional Apathy 
Scale)34 35
CARE- MND data 
request
Clinical phenotype data
 ► Date of diagnosis
 ► Age at diagnosis
 ► Classification of MND
 ► Site of onset
 ► Family history
CARE- MND or MND- 
SMART data request
ALS- FRS (R) (Amyotrophic Lateral 
Sclerosis Functional Rating Scale- 
Revised)14
ECAS (Edinburgh Cognitive and 
Behavioural ALS Screen)36
MND- SMART data 
request
MND- SMART recruitment and 
retention data
 ► Date MND- SMART Participant 
Information Sheet given
 ► Date of screening
 ► Date of randomisation
 ► Date of withdrawal
 ► Date of last appointment if 
withdrawn
 ► Reason for withdrawal if 
provided
 ► Status (alive/deceased)
 ► Date of death (if applicable)
CARE, Clinical Audit Research and Evaluation; MND, motor neuron 
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selected to align with the criteria for MND- SMART to 
ensure maximum overlap in the two participant groups.
Public and patient involvement statement
PwMND were first involved in the research when they were 
emailed the ACT- Q, Participant Information Sheet and 
Consent Form and asked to provide feedback. PwMND 
were asked to consider the questionnaire structure of the 
ACT- Q, provide an estimate of the time taken to complete 
and asked to suggest any additional factors which may 
influence their attitudes towards trial participation.
PwMND were invited to provide feedback on Partic-
ipant Information Sheets and Consent Forms, particu-
larly clarity of study aims, and additional aspects of MND 
which may potentially affect trial participation. Feed-
back from these individuals was used to refine the list of 
exploratory covariates in the study, and particularly the 
items included on the ACT- Q. Time required to partici-
pate in the research was based on feedback from patients, 
existing time- to- complete data for each of the established 
questionnaires, with additional time for potential commu-
nication or physical difficulties.
All participants in the study, who chose to, will be sent 
a copy of the study findings. PwMND and their caregivers 
will be consulted regarding the best way to disseminate 
findings and provide feedback on initial versions of the 
study summary documents to ensure clarity of presenta-
tion and suitability for this audience.
ANALYSIS PLAN
The study questionnaires will be grouped into domains to 
reduce the number of candidate variables in the analysis 
as shown in table 4. The total scores of individual ques-
tionnaires will be summed into an overall summary score 
for each domain, which will be included in the subsequent 
analysis. As all scores represent the same directionality 
(higher score indicates greater impairment) a summed 
score will provide an overall indication of the level of 
impairment for each individual per grouped domain.
We will present the mean scores for each assessment, 
displayed in the factor groupings discussed above, with 
ranges and SD.
Scoring the ACT-Q
The Attitudes towards Clinical Trial Participation Ques-
tionnaire (ACT- Q) is a brief trial- specific questionnaire 
to quantify FIT- P- MND’s attitudes towards involvement 
in research, and multi- arm clinical trials in particular 
(table 5). Developed by the investigators, based on Kessel’s 
survey25 and Ellis’ tripartite model17 on factors impacting 
trial engagement.
Each potential response is scored on the participant’s 
rating of its importance to their decision- making process 
and an overall score for each factor will be produced per 
individual. Items 6, 7 and 13 will be reverse scored, indi-
cating less agreement with the statement.
The final aspect of this questionnaire is evaluating FIT- 
P- MND participants’ understanding of five key features 
of design. Respondents will indicate on a 5- point scale to 
represent level of understanding.
Statistical analysis
We will use logistic regression to model the impact of 
the aforementioned independent variables on the FIT- 
P- MND participant’s decision to enrol or not enrol in 
MND- SMART. All variables will be considered in univar-
iate and subsequently multivariable analysis. Results will 
be presented as OR and 95% CIs.
12 months after the obtaining the questionnaire 
responses, we will extract participation data from 
MND- SMART.
As this is an exploratory study with nine categories of 
covariates, we will not be using an adjusted alpha- level 
to correct for multitesting. The Bonferroni method of 
correcting p values may not be suitable for this analysis 
as hypotheses are predefined, not all variables must be 
significant to reject the null hypothesis and descriptive 
statistics will also be of relevant when interpreting the 
findings.26
Table 3 Criteria for FIT- participation- MND participants and 
caregivers
For FIT- participation- MND participant with MND
Inclusion 
criteria
 ► Over 18
 ► Confirmed diagnosis of MND (including 
the following subtypes: amyotrophic lateral 
sclerosis by El Escorial Criteria (possible, 
probable and definite), primary lateral 
sclerosis and progressive muscular atrophy)
 ► Able to provide informed consent (proxy 
signature accepted if limb dysfunction)
 ► Fluent in English
Exclusion 
criteria
 ► Diagnosis of Frontotemporal Dementia 
(FTD- MND)
 ► Unable to provide informed consent




 ► Able and willing to complete a brief 
questionnaire regarding the participant’s 
behaviour
 ► Family member, spouse, relative, friend or 
partner for pwMND
 ► Primary caring responsibilities for pwMND
 ► Fluent in English
Exclusion 
criteria
 ► Paid carers–excluded to ensure they know the 
person pre- MND diagnosis
 ► Not fluent in English
 ► Unable to provide informed consent
 ► Diagnosis of MND
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Table 4 Grouping of exploratory covariates
Grouping Assessment or data included Impairment thresholds
Attitudes ACT- Q (Attitudes towards Clinical Trial 
Participation Questionnaire)
Not applicable
Quality of life CDC HQOL-4 (Centre for Disease Control and 
Prevention- Health- Related Quality of Life)33
Not applicable




ECAS (Edinburgh Cognitive and Behavioural 
ALS Screen)36
 ► Total score is 136 where a higher score indicates better 
performance. Scores below 105 are considered abnormal
Behavioural 
change
b- DAS (Brief Dimensional Apathy Scale)34 35 Each subscale has a minimum score of 0 (least apathy) and a 
maximum score of 9 (most apathy)




ECAS Behavioural Screen Subscale Carer- completed behavioural change screen
Indicate yes/no to symptoms, score 1 for every symptoms present 
out of 10
Carer- completed psychosis screen




ALS- FRS (R) (Amyotrophic Lateral Sclerosis 
Functional Rating Scale- Revised)14
Twelve tasks rated from 0 (cannot do) to 4 (normal ability). Summed 
score between 0 (worst) and 48 (best)
Neuropsychiatric HADS (Hospital Anxiety and Depression 
Scale)27 28
Maximum total score is 24








PHQ-9 (9- Item Patient Health Questionnaire)30 
31
Depression:







Item 9 scores from (0) not at all
1. Several days
2. More than half the days
3. Nearly every day
Scores of >1 indicates presence of suicidal ideation
Clinical 
phenotype
 ► MND classification Not applicable
 ► Site of onset (spinal, bulbar, pure 
respiratory)
 ► Age at diagnosis



















pen: first published as 10.1136/bm





7Beswick E, et al. BMJ Open 2021;11:e044996. doi:10.1136/bmjopen-2020-044996
Open access
Missing data
If particular covariates, certain assessments or question-
naires, are not completed fully by the majority of partic-
ipants, we will consider removing this variable from 
analysis. Missing data within individual questionnaires 
will be handled using multiple imputation. Incomplete 
questionnaires will not be returned to participants. As 
participants do not require a caregiver to participate, a 
missing behavioural questionnaire will not be included in 
thresholds for missing data. The covariate of behavioural 
change will be included where possible.
MANAGEMENT OF POTENTIAL RISK
All FIT- P- MND participants, and caregivers, will provide 
informed consent and acknowledge they have read the 
study information. Participant- facing documentation 
highlights the voluntary nature of the study and require-
ments of participation. There are no direct risks involved 
in participating, however, as some of the questionnaires 
focus on mental health we acknowledge this may be 
distressing, clinical teams will be informed of any signifi-
cant scores. The individual’s GP will also be contacted to 
inform them of study involvement.
A potential issue is fatigue, which may be induced by 
the length of assessment administration. Participants will 
be encouraged to inform the researcher if they are expe-
riencing any and the option to complete at home enables 
participants who have significant issues with physical and 
mental fatigue to take breaks and complete the question-
naires at their own pace.
Data management and confidentiality of FIT- P- MND 
participants will be managed by assigning participant ID 
codes to anonymise responses. The use of identifiable 
information will be minimised.
ETHICS AND DISSEMINATION
This research is co- sponsored by the University of Edin-
burgh and NHS Lothian. Representatives from the 
Academic and Clinical Central Office for Research and 
Development have reviewed and approved this project. 
Ethical approval was provided by the West of Scotland 
Research Ethics Committee 3 on 12th May 2020 (REC 
Reference: 20/WS/0067).
Only pwMND who have provided prior consent to be 
contacted about ongoing research on their CARE- MND 
record will be invited to participate. The Anne Rowling 
Regenerative Neurology Clinic hosts the register, the data 
processor at the clinic will contact the potential partic-
ipants’ MND nurse prior to posting recruitment packs.
At the end of the study a lay summary will be sent to the 
participants, or their nominated representative, for indi-
viduals who have indicated they would like to receive one 
on their Consent Form. The results will be disseminated 
to the community at engagement events and social media. 
Fully anonymised data will be uploaded to a persistent 
DOI at the Open Science Framework; ORCID ID 0000-
0001-9843-0778: https:// osf. io/ fxnwv/. Agreement with 
this data storage policy is included in the Consent Form. 
We intend to publish the results of this project in a peer- 
reviewed journal and presented at academic conferences.
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1. The time commitment required to 
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